Latest Insider Transactions at Senti Biosciences, Inc. (SNTI)
This section provides a real-time view of insider transactions for Senti Biosciences, Inc. (SNTI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Senti Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Senti Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2025
|
Celadon Partners Spv 24 > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
9,777,000
+50.0%
|
-
|
|
Mar 10
2025
|
New Enterprise Associates 15, L.P. |
BUY
Conversion of derivative security
|
Direct |
3,333,000
+46.89%
|
-
|
|
Mar 10
2025
|
Bayer Healthcare LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,222,000
+44.16%
|
-
|
|
Mar 10
2025
|
Kanya Rajangam Pres. & Chief Med. & Dev. Off. |
BUY
Conversion of derivative security
|
Indirect |
33,000
+50.0%
|
$66,000
$2.25 P/Share
|
|
Mar 07
2025
|
K Lu Timothy CEO and Interim PFO and PAO |
BUY
Grant, award, or other acquisition
|
Direct |
642,358
+47.0%
|
-
|
|
Mar 07
2025
|
Kanya Rajangam Pres. & Chief Med. & Dev. Off. |
BUY
Grant, award, or other acquisition
|
Direct |
78,363
+47.39%
|
-
|
|
Feb 06
2025
|
K Lu Timothy CEO and Interim PFO and PAO |
SELL
Open market or private sale
|
Direct |
545
-0.66%
|
$2,180
$4.36 P/Share
|
|
Feb 06
2025
|
Kanya Rajangam Pres. & Chief Med. & Dev. Off. |
SELL
Open market or private sale
|
Direct |
182
-2.07%
|
$728
$4.37 P/Share
|
|
Feb 04
2025
|
K Lu Timothy CEO and Interim PFO and PAO |
SELL
Open market or private sale
|
Direct |
3,922
-4.53%
|
$15,688
$4.07 P/Share
|
|
Feb 04
2025
|
Kanya Rajangam Pres. & Chief Med. & Dev. Off. |
SELL
Open market or private sale
|
Direct |
1,297
-12.84%
|
$5,188
$4.07 P/Share
|
|
Feb 01
2024
|
Deborah Knobelman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
101,000
+43.53%
|
-
|
|
Feb 01
2024
|
K Lu Timothy CEO and Interim PFO and PAO |
BUY
Grant, award, or other acquisition
|
Direct |
306,000
+26.12%
|
-
|
|
Feb 01
2024
|
Kanya Rajangam Pres. & Chief Med. & Dev. Off. |
BUY
Grant, award, or other acquisition
|
Direct |
101,000
+50.0%
|
-
|
|
Oct 03
2022
|
Deborah Knobelman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
Jun 08
2022
|
Dynamics Sponsor LLC Director |
SELL
Other acquisition or disposition
|
Direct |
6,465,500
-100.0%
|
-
|
|
Jun 08
2022
|
Dynamics Sponsor LLC Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,750,000
+47.07%
|
-
|
|
Jun 08
2022
|
Omid Farokhzad Director |
BUY
Grant, award, or other acquisition
|
Indirect |
250,000
+50.0%
|
$2,500,000
$10.0 P/Share
|
|
Jun 08
2022
|
Omid Farokhzad Director |
SELL
Other acquisition or disposition
|
Indirect |
4,518,097
-69.88%
|
-
|
|
Jun 08
2022
|
Omid Farokhzad Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
5,750,000
+47.07%
|
-
|
|
Jun 08
2022
|
David R Epstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
112,519
+47.72%
|
-
|